Other programs in preclinical development include additional ... limiting their impact on the brain. In a phase 1b/2a open-label clinical trial of males aged 12 to 17 with ASD, AB-2004 exhibited ...

Getting drugs from the bloodstream into the brain is notoriously difficult because ... fluid and had a positive effect on neurocognitive development 1. No serious treatment-related adverse events ...

Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide (ASO) therapy targeting a single, undisclosed central nervous system ...